The ONSHORE Manufacturing Act incentivizes the domestic production of essential medical products and drugs by providing tax credits for manufacturing income, advanced equipment investments, and environmental compliance.
Marsha Blackburn
Senator
TN
The ONSHORE Manufacturing Act aims to strengthen domestic medical supply chains by providing targeted tax incentives for the U.S.-based production of essential drugs, medical devices, and active pharmaceutical ingredients. The bill establishes credits for qualified manufacturing income, investments in advanced medical manufacturing equipment, and the installation of environmental compliance technology. Additionally, it mandates annual federal reporting to track the impact of these incentives on supply chain resiliency and the reduction of medical product shortages.
ONSHORE Act Offers 10.5% Tax Break to Bring Medical Manufacturing Back to U.S. Soil
If the last few years taught us anything, it’s that waiting on a cargo ship for essential medicine is a recipe for disaster. The ONSHORE Manufacturing Act is a direct attempt to fix that by dangling a massive carrot in front of drug and medical device makers. Starting in 2027, the bill creates a new tax credit equal to 10.5% of a company’s income from making critical medical gear right here in the U.S. Whether it’s the active ingredients in your antibiotics or the specialized sensors in a ventilator, the goal is to make 'Made in America' the default for your medicine cabinet.
The Payday for Producers
This isn't just a generic pat on the back for businesses; it’s a calculated financial incentive. The bill allows companies to offset both their regular income tax and the alternative minimum tax, but there’s a catch to keep things honest: the credit is capped at 50% of the W-2 wages they pay to workers involved in that domestic production. For a factory manager in Ohio or a biotech firm in North Carolina, this means the more they invest in American labor, the more they save. However, the bill uses the phrase 'significant part' when describing how much of the manufacturing must happen domestically. While this is meant to be flexible, it leaves a bit of a gray area for the Treasury Department to define—meaning we’ll have to watch closely to ensure companies aren't just doing the final packaging here while still relying on overseas factories for the heavy lifting.
Tech Upgrades and Green Requirements
Beyond just making the pills, the bill looks at the machines and the environment. Section 3 introduces a sliding scale credit for 'advanced medical manufacturing equipment'—starting at 30% for gear installed before 2031 and phasing out by 2032. This is for the high-tech stuff that speeds up production or helps prevent drug shortages. Additionally, Section 4 offers a similar 30% credit for manufacturers to upgrade their facilities to meet Clean Air and Clean Water Act standards. For someone living near an industrial zone, this is a win-win: more local jobs and potentially cleaner local infrastructure as companies modernize to grab these tax breaks.
Accountability and the Long Game
The bill doesn't just hand out checks and walk away. It requires the IRS, the VA, the Department of Defense, and the FDA to report back to Congress every year. They’ll be looking at whether these credits actually stopped drug shortages and if the military is successfully buying more American-made supplies. While this sounds great for national security and supply chain stability, the cost is essentially a reduction in tax revenue. The real-world test will be whether the benefit of having a stable, local supply of life-saving medicine outweighs the billions in tax credits being handed out to large pharmaceutical and medical device corporations.